Sanofi: cablivi approval recommended by CHMP
(CercleFinance.com) - Sanofi has said that the CHMP of the European Medicines Agency has recommended the approval of Cablivi (caplacizumab) in Europe for the treatment of episodes of acquired thrombotic thrombocytopenic purpura (acquired PTT) in adults.
The European Commission will review the CHMP's recommendation and its final decision on this product's application for marketing authorisation in the European Union will be known in the next few months.
Cablivi is Ablynx's first Nanobody drug to obtain a favourable opinion from the CHMP. If approved, it will be the first therapeutic agent specifically indicated in the treatment of acquired PTT.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The European Commission will review the CHMP's recommendation and its final decision on this product's application for marketing authorisation in the European Union will be known in the next few months.
Cablivi is Ablynx's first Nanobody drug to obtain a favourable opinion from the CHMP. If approved, it will be the first therapeutic agent specifically indicated in the treatment of acquired PTT.
Copyright (c) 2018 CercleFinance.com. All rights reserved.